Cutaneous Manifestations of COVID-19 Vaccination and COVID-19 Infection: a Questionnaire-based, Multi-center Study in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause various cutaneous complications, including dermatologic adverse reactions to SARS-CoV-2 vaccines reported by several studies. Objective: To describe the clinical characteristics of cutaneous complications of SARS-CoV-2 infection and adverse reactions to SARS-CoV-2 vaccines, and to determine the risk factors for cutaneous manifestations. Methods: A questionnaire-based survey in 12 hospitals in Korea. Results: After receiving SARS-CoV-2 vaccinations, 20.23% and 5.94% of the respondents reported new-onset cutaneous lesions or aggravation of preexisting cutaneous conditions, respectively. Respondents who developed new cutaneous lesions after COVID-19 were significantly older than those who did not (p = 0.001). Systemic symptoms of SARS-CoV-2 vaccination (fever, chill, cough, sore throat, and myalgia) were associated with higher risk for new-onset cutaneous lesions (p < 0.05). Myalgia was the only systemic symptom of SARS-CoV-2 vaccination that was associated with higher risk for the aggravation of preexisting cutaneous conditions (p = 0.011). Following coronavirus 2019 (COVID-19) diagnosis, 13.3% and 9.7% of the respondents reported new skin lesions and aggravation of preexisting cutaneous conditions, respectively. Respondents with new cutaneous lesions were significantly older than those without new cutaneous lesions (p = 0.046). Systemic COVID-19 symptoms were significantly more common in respondents who developed new cutaneous lesions than in those who did not (p < 0.001). The proportion of respondents with underlying autoimmune diseases was significantly higher in those with cutaneous COVID-19 complications than in those without such complications (p = 0.038). Conclusion: This study offers insights into the characteristics of cutaneous manifestations of SARS-CoV-2 vaccination and infection in Korea.
Abstract
Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause various cutaneous complications, including dermatologic adverse reactions to SARS-CoV-2 vaccines reported by several studies. Objective: To describe the clinical characteristics of cutaneous complications of SARS-CoV-2 infection and adverse reactions to SARS-CoV-2 vaccines, and to determine the risk factors for cutaneous manifestations. Methods: A questionnaire-based survey in 12 hospitals in Korea. Results: After receiving SARS-CoV-2 vaccinations, 20.23% and 5.94% of the respondents reported new-onset cutaneous lesions or aggravation of preexisting cutaneous conditions, respectively. Respondents who developed new cutaneous lesions after COVID-19 were significantly older than those who did not (p = 0.001). Systemic symptoms of SARS-CoV-2 vaccination (fever, chill, cough, sore throat, and myalgia) were associated with higher risk for new-onset cutaneous lesions (p < 0.05). Myalgia was the only systemic symptom of SARS-CoV-2 vaccination that was associated with higher risk for the aggravation of preexisting cutaneous conditions (p = 0.011). Following coronavirus 2019 (COVID-19) diagnosis, 13.3% and 9.7% of the respondents reported new skin lesions and aggravation of preexisting cutaneous conditions, respectively. Respondents with new cutaneous lesions were significantly older than those without new cutaneous lesions (p = 0.046). Systemic COVID-19 symptoms were significantly more common in respondents who developed new cutaneous lesions than in those who did not (p < 0.001). The proportion of respondents with underlying autoimmune diseases was significantly higher in those with cutaneous COVID-19 complications than in those without such complications (p = 0.038). Conclusion: This study offers insights into the characteristics of cutaneous manifestations of SARS-CoV-2 vaccination and infection in Korea.
참고문헌 (26)
- "Coronavirus Disease 19 (COVID-19)" (2023)[URL]
- "A comprehensive view of global deaths directly and indirectly associated with the COVID-19 pandemic"[URL]
- Gambichler T, "Cutaneous findings following COVID-19 vaccination : review of world literature and own experience", J Eur Acad Dermatol Venereol, 36, pp.172~180 (2022)
- Nakashima C, "Cutaneous manifestations of COVID-19 and COVID-19 vaccination", J Dermatol, 50, pp.280~289 (2023)
- Bellinato F, "Cutaneous adverse reactions associated with SARS-CoV-2vaccines", J Clin Med, 10, pp.5344~ (2021)
- Pourani MR, "Cutaneous adverse events related to COVID-19 vaccines : A cross-sectional questionnairebased study of 867 patients", Dermatol Ther, 35, pp.e15223~ (2022)
- Català A, "Cutaneous reactions after SARS-CoV-2 vaccination : a crosssectional Spanish nationwide study of 405 cases*", Br J Dermatol, 186, pp.142~152 (2022)
- Recalcati S, "Cutaneous manifestations in COVID-19 : a first perspective", J Eur Acad Dermatol Venereol, 34, pp.e212~e213 (2020)
- Hatami P, "Cutaneous manifestations of COVID-19 in children : Practical points for clinicians", J Skin Stem Cell, 8, pp.e122260~ (2021)
- "The use of the WHO-UMC system for standardized case causality assessment"[URL]
- Ramasamy MN, "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2", 3 trial, 2021, pp.396, 1979~1993
- Bae S, "Adverse reactions following the first dose of ChAdOx1 nCoV-19vaccine and BNT162b2 vaccine for healthcare workers in South Korea", J Korean Med Sci, 36, pp.e115~ (2021)
- Robinson LB, "Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines", JAMA Dermatol, 157, pp.1000~1002 (2021)
- Alemayehu A, "COVID-19 vaccine side effect : age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia : a community-based study", SAGE Open Med, 10, pp.20503121221108616~ (2022)
- Gee J, "First month of COVID-19 vaccine safety monitoring-United States", MMWR Morb Mortal Wkly Rep, 70, pp.283~288 (2021)
- Urakawa R, "Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan : a cross-sectional study", BMC Infect Dis, 22, pp.179~ (2022)
- Siegrist CA, "Mechanisms underlying adverse reactions to vaccines", J Comp Pathol, 137, pp.S46~S50 (2007)
- Bostan E, "New-onset leukocytoclastic vasculitis after COVID-19 vaccine", Int J Dermatol, 60, pp.1305~1306 (2021)
- Mücke VT, "First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2 : a case report", BMC Infect Dis, 21, pp.958~ (2021)
- Cyrenne BM, "Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine", J Eur Acad Dermatol Venereol, 35, pp.e546~e548 (2021)
- für das Alter NA, "Risikofaktor Komorbi-ditäten bei COVID-19-Erkrankung", Pneumologie, 74, pp.639~640 (2020)
- Tan CC, "Cutaneous manifestations of COVID-19 in a tertiary COVID-19 referral hospital in the Philippines", JAAD Int, 7, pp.44~51 (2022)
- Galván Casas C, "Classification of the cutaneous manifestations of COVID-19 : a rapid prospective nationwide consensus study in Spain with 375 cases", Br J Dermatol, 183, pp.71~77 (2020)
- de Masson A, "Chilblains is a common cutaneous finding during the COVID-19 pandemic : A retrospective nationwide study from France", J Am Acad Dermatol, 83, pp.667~670 (2020)
- Gottlieb M, "Dermatologic manifestations and complications of COVID-19", Am J Emerg Med, 38, pp.1715~1721 (2020)
- Tamai M, "Cutaneous manifestations of coronavirus disease 2019 patients in Japan", J Dermatol, 49, pp.872~878 (2022)